We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
+50.84%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$607M
AUM Growth
+$134M
Cap. Flow
-$71.4M
Cap. Flow %
-11.75%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
2
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$54.6M
2
EPZM
Epizyme, Inc
EPZM
+$13.3M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$2.77M
4
INSM icon
Insmed
INSM
+$712K

Sector Composition

Rank Sector Weight
1 Healthcare 93.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
1
10x Genomics
TXG
$5.87B
$521M 85.84%
6,837,253
– –
AERI
2
DELISTED
Aerie Pharmaceuticals
AERI
$40.4M 6.66%
1,672,714
– –
INSM icon
3
Insmed
INSM
$23.2B
$21M 3.46%
880,016
-35,000
-4% -$712K
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$14.5M 2.4%
591,304
-897,140
-60% -$13.3M
XLRN
5
DELISTED
Acceleron Pharma
XLRN
$10M 1.65%
188,602
– –
AIMT
6
DELISTED
Aimmune Therapeutics
AIMT
– –
-2,605,499
Closed -$54.6M
ALDR
7
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-146,800
Closed -$2.77M

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q4 2019 Portfolio in Review

As of Q4 2019, Foresite Capital Management II held 7 positions worth $607M, up 28% from $473M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management II withdrew a net $71.4M in Q4 2019, closing 2 positions and reducing 2 holdings. Its most notable exit was Aimmune Therapeutics, an estimated $54.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 82% a quarter earlier.

  • Foresite Capital Management II's biggest Q4 2019 reduction was Epizyme, Inc, cutting an estimated $13.3M.
  • Foresite Capital Management II fully exited Aimmune Therapeutics in Q4 2019, selling an estimated $54.6M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $607M portfolio in Q4 2019.
  • Foresite Capital Management II opened 0 new positions and closed 2 in Q4 2019.
  • Foresite Capital Management II's portfolio value rose 28% quarter-over-quarter to $607M.

Based on Foresite Capital Management II's 13F filing for Q4 2019, filed 5 Feb 2020.